Transcatheter closure of the left atrial appendage

This publication provides information about left atrial appendage (LAA) closure, a treatment designed to lower the risk of stroke in some patients with atrial fibrillation (AF).

What is the risk of stroke in patients with atrial fibrillation?

Atrial fibrillation (AF) is a very common heart rhythm disorder which is present when the heart’s two upper chambers, the left and right atria, beat in a fast and irregular manner.

AF is present in 1 to 2% of the adult population overall, although the prevalence of AF in people over 65 is thought to be about 8%, and this population group is also most at risk of stroke. AF is more common if other forms of heart and vascular disease are present (e.g. hypertension, coronary artery disease, and heart valve disease).

Some patients may find that AF causes uncomfortable symptoms such as palpitations or shortness of breath, but some patients have no symptoms at all.

As a rule, people with untreated AF will have a five times greater risk of stroke and two fold greater risk of dying, as compared to similar people without AF.

How can atrial fibrillation cause stroke?

During AF, irregular heartbeats can cause the blood to pool in the left atrial appendage. This may result in the development of blood clots in the LAA.

If a blood clot is pumped out of the heart to the brain, it could block the flow of blood in small vessels and cause a stroke (see Figure 1).

What is the most common treatment for preventing AF-related stroke?

The risk of an AF-related stroke in patients depends on a number of factors, including age, a history of high blood pressure, heart failure, diabetes, and previous stroke or mini-stroke. On the basis of these factors, the doctor will be able to assess an individual’s risk of stroke, and recommend an anticoagulant (sometimes referred to as a blood thinner) to reduce the blood’s ability to clot. The antiplatelet medication aspirin is significantly less effective than anticoagulants for patients with AF who are at an increased risk of stroke, and for this reason it is no longer recommended by NICE for AF-related stroke prevention.

One of the most commonly prescribed treatments used in patients with AF is a drug called warfarin. Warfarin significantly reduces the risk of AF-related stroke when taken regularly.

What is the left atrial appendage?

The left atrial appendage is a muscular pouch connected to the left atrium of the heart. A review of studies has shown that in the majority of
patients with atrial fibrillation almost all clots form within the appendage. The LAA contributes to the heart’s pumping action during the normal rhythm and produces a hormone that helps control the fluid content of the body, but it loses these functions during atrial fibrillation. Atrial appendages are sometimes removed during heart surgery without causing any problems.

What is left atrial appendage closure?

Unfortunately, some patients at high risk of stroke are either unable or unwilling to take anticoagulants because of associated risks, or side effects.

An alternative to medication for patients with AF at high risk of stroke is to close off the appendage with a medical closure device (see Figure 2).

The device is designed to close the left atrial appendage (which is known to be the main source of blood clots in patients with AF), preventing clots from forming in the LAA, or breaking free from it and travelling to the brain.

How is the LAA closure procedure carried out?

Transcatheter closure of the LAA is carried out in a cardiac catheterisation laboratory, a specially equipped cardiology room where patients with heart rhythm disorders are examined and treated, or in an electrophysiology laboratory.

The procedure lasts about 45-90 minutes.

The procedure is usually done under general anaesthesia (but may also be done under sedation in some instances).

During the procedure, a cardiac ultrasound (or echo) examination is undertaken (to get clear pictures of the heart) by placing an echo probe in the oesophagus.

A small cut (or incision) is made in the groin and through this opening a small plastic tube (catheter) is inserted into a vein in the leg. This catheter contains the compressed umbrella shaped device which is used to close the opening of the left atrial appendage.

Using X-rays and ultrasound images, the catheter is guided into the heart. The umbrella-like device is passed through the catheter and into position within the LAA. As the compressed device is pushed from the end of the catheter tip it expands, thereby blocking the mouth of the left atrial appendage (see Figure 3).

The patient may need to return to their doctor for periodic follow-up visits over the next year. The doctor will also advise the patient when normal daily activities can be resumed. Typically all strenuous activity should be avoided for one month following the procedure. If the patient experiences shortness of breath or chest pain, they should seek medical help immediately.

What happens after the procedure?

Recovery following the procedure will take about 24 hours. After recovery from anaesthesia and with adequate bed rest the patient should be able to sit up and walk around. Before leaving the hospital, tests such as an echocardiogram (ultrasound scan of the heart) may be performed to make sure the device is still positioned correctly.
As the procedure is minimally invasive, the recovery process is likely to be quick and easy. There may be an adhesive plaster used in the groin where the sheath was inserted. The patient may also have a sore throat due to the use of imaging probe (trans-oesophageal echo).

What medication will the patient need to take?

Before leaving the hospital, the doctor will provide advice on medications. They may prescribe warfarin for a period of time before and after the procedure. Once the warfarin is discontinued the patient may be required to take clopidogrel or an equivalent antiplatelet medicine with or without aspirin. The decision of how long the patient should take this medication is at the discretion of the doctor.

What are the benefits of LAA closure?

The main benefit of this procedure is that it potentially eliminates the need to take warfarin.

In the majority of patients warfarin is continued for a minimum period of six to eight weeks post procedure so as to allow time for the implanted device to bed in. During this time the body will form a new layer of natural tissue over the device, sealing it into place.

What evidence is there to support this procedure?

Several LAA closure devices are approved and available today. However the level of evidence differs from one to another.

Strong clinical evidence has been published on the watchman device showing that watchman LAA closure is at least as good as warfarin in terms of reducing stroke risk. Recent long term data on this device even support an improved efficacy compared to warfarin at four and five years. The doctor may also take into account a patient’s LAA anatomy to choose the most suitable device.

Are there any risks associated with the procedure?

No medical procedure is entirely without risk. It is important to remember that a doctor will not recommend this procedure if he/she did not believe the potential risks were outweighed by the likely benefits to the patient’s health.

Most of the complications are rare but some are serious. The doctor will discuss the risks with the patient.

The most common complications from this procedure include, but are not limited to:

- Bleeding or bruising in the area of the groin where the catheter is inserted
- Stroke
- Device malposition or embolisation
- Bleeding around the heart
- Infection
- Oesophageal damage

Are some patients not suitable for left atrial appendage closure?

Individuals with blood clots in their heart (intracardiac thrombus) are not eligible to have the LAA closure procedure.

If a patient has an active infection producing bacteria in the blood they may receive the device only after the infection is gone.

Other specific contraindication will be explained by the doctor.

Acknowledgements: AF Association would like to thank all those who helped in the development of this publication. Particular thanks are given to Dr Francis Murgatroyd, (EP), Professor A John Camm (Professor of Clinical Cardiology, Cardiac and Vascular Sciences), Professor Richard Schilling (Consultant Cardiologist) and Dr John Foran (EP).